Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.50 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PRCP | P42785 | 1/20 | 0.46 |
| ▸ | EBP | Q15125 | 1/20 | 0.46 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1608042 | 0.80 | DRD2 (0.59) | DRD2DRD3SIGMAR1DRD4NFKB1 | |
| SCHEMBL29427014 | 0.80 | DRD2 (0.59) | DRD2DRD3SIGMAR1DRD4NFKB1 | |
| SCHEMBL22850666 | 0.78 | KDM1A (0.53) | DRD2DRD3HTR2AHTR2CHTR2B | |
| SCHEMBL20187570 | 0.78 | SLC6A2 (0.47) | HTR2AHTR2CHTR2B | |
| SCHEMBL1424770 | 0.77 | CHRNB4 (0.64) | DRD2DRD3OPRM1OPRD1CHRNB4 | |
| SCHEMBL1424774 | 0.77 | CHRNB4 (0.64) | DRD2DRD3OPRM1OPRD1CHRNB4 | |
| SCHEMBL1658753 | 0.77 | HDAC4 (0.56) | DRD2DRD3SIGMAR1DRD4NFKB1 | |
| SCHEMBL1661863 | 0.77 | HDAC4 (0.61) | DRD2DRD3SIGMAR1DRD4NFKB1 | |
| Bromide SCHEMBL1425051 | 0.76 | CHRNB4 (0.62) | DRD2DRD3OPRM1OPRD1CHRNB4 | |
| Bromide SCHEMBL1425052 | 0.76 | CHRNB4 (0.62) | DRD2DRD3OPRM1OPRD1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | DRD2 4539/4885DRD3 4404/4885OPRM1 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.